Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis

摘要

IntroductionPatients with urothelial carcinoma (uc) have a poor prognosis after progression on first-line cisplatin-based chemotherapy. Real-world data about second-line cytotoxic therapies are limited. We sought to characterize patients with metastatic uc who receive more than 1 line of systemic therapy and to describe their treatments and outcomes.